4,869 IQVIA Holdings Inc. $IQV Shares Bought by Bessemer Group Inc.

Bessemer Group Inc. boosted its stake in IQVIA Holdings Inc. (NYSE:IQV – Free Report) by 108.7% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 9,347 shares of the medical research company’s stock after buying an additional 4,869 shares during the period. Bessemer Group Inc.’s holdings in IQVIA were worth $2,514,000 as of its most recent SEC filing.

A number of other hedge funds have also modified their holdings of IQV. Pension & Wealth Management Advisors Inc. bought a new stake in shares of IQVIA in the 3rd quarter valued at approximately $30,000. Compass Financial Management LLC bought a new position in IQVIA in the second quarter worth $27,000. Elevation Wealth Partners LLC raised its holdings in shares of IQVIA by 218.8% in the 2nd quarter. Elevation Wealth Partners LLC now owns 153 shares of the medical research company’s stock worth $30,000 after buying an additional 105 shares in the last quarter. Balance Wealth Partners LLC bought a new stake in IQVIA during the third quarter worth about $43,000. Finally, Caitlin John LLC bought a new stake in IQVIA during the 2nd quarter worth about $31,000. 89.62% of the stock is currently owned by institutional investors and hedge funds.

IQVIA Trading Down 1.9%

Shares of IQV stock opened at $245.68 on Friday. The firm has a market capitalization of $40.49 billion, a PE ratio of 29.85, a PEG ratio of 2.18 and a beta of 1.16. The stock has a fifty day simple moving average of $267.01 and a two-hundred day simple moving average of $212.56. The company has a debt-to-equity ratio of 2.18, a quick ratio of 0.83 and a current ratio of 0.83. IQVIA Holdings Inc. has a 52-week low of $154.50 and a 52-week high of $284.50.

IQVIA (NYSE:IQV – Get Free Report) last issued its quarterly earnings results on Tuesday, October 27th. The medical research company reported $3.34 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.26 by $0.08. IQVIA had a return on equity of 30.02% and a net margin of 8.05%. The company had revenue of $4.43 billion during the quarter, compared to the consensus estimate of $4.37 billion. During the same period last year, the company earned $3.00 earnings per share. IQVIA’s revenue was up 8.0% on a year-over-year basis. On average, analysts predict that IQVIA Holdings Inc. will post 11.53 EPS for the current fiscal year.

Insider Buying and Selling

In other news, insider Eric Sherbet sold 4,446 shares of the firm’s stock in a transaction that occurred on Monday, November 9th. The shares were sold at an average price of $278.83, for a total transaction of $1,239,678.18. Following the sale, the insider owned 24,989 shares of the company’s stock, valued at $6,967,682.87. This trade represents a 15.10% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider James G. Berkshire sold 2,668 shares of the business’s stock in a transaction that occurred on Wednesday, September 2nd. The shares were sold at an average price of $261.33, for a total value of $697,228.44. Following the completion of the sale, the insider owned 10,890 shares of the company’s stock, valued at $2,845,883.70. This trade represents a 19.68% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. 1.70% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

Several equities analysts have weighed in on the company. Evercore increased their target price on IQVIA from $275.00 to $290.00 and gave the company an “outperform” rating in a research note on Tuesday, October 6th. Weiss Ratings lowered IQVIA from a “hold (c+)” rating to a “sell (d+)” rating in a report on Wednesday, October 28th. Royal Bank Of Canada upped their price target on shares of IQVIA from $247.00 to $319.00 and gave the company an “outperform” rating in a research note on Tuesday, September 29th. JPMorgan Chase & Co. lifted their price target on IQVIA from $295.00 to $325.00 and gave the company an “overweight” rating in a research note on Wednesday, October 28th. Finally, Leerink Partners upped their price target on shares of IQVIA from $280.00 to $310.00 and gave the company an “outperform” rating in a research report on Thursday, October 8th. Two equities research analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $294.21.

View Our Latest Stock Report on IQVIA

IQVIA Profile

(Free Report)

IQVIA Holdings Inc. provides clinical research services, healthcare data and analytics, and technology solutions to pharmaceutical, biotechnology, medical-device, and other healthcare organizations. Its services support the development and commercialization of medicines and other healthcare products. The company’s offerings include clinical trial planning and management, real-world data and evidence, consulting, and software and technology platforms for life sciences research and commercial operations.

Read More

Institutional Ownership by Quarter for IQVIA (NYSE:IQV)

Receive News & Ratings for IQVIA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IQVIA and related companies with MarketBeat.com's FREE daily email newsletter.